Investors have been keenly watching BeiGene’s blood cancer drug Brukinsa for clues to how much market share it can snatch from Johnson & Johnson and AbbVie’s Imbruvica. But Monday, Brukinsa came up short in a head-to-head trial against its blockbuster competition, failing to outdo Imbruvica at producing complete and very good partial responses.
